This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MYXDA Stock Overview

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details

MYXDA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 51.6% below our estimate of its fair value

Revenue is forecast to grow 9.2% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Mayne Pharma Group Limited Competitors

Probiotec

ASX:PBP

AU$242.3m

Starpharma Holdings

ASX:SPL

AU$41.0m

Incannex Healthcare

ASX:IHL

AU$65.1m

Clarity Pharmaceuticals

ASX:CU6

AU$1.5b

Price History & Performance

Summary of share price highs, lows and changes for Mayne Pharma Group
Historical stock prices
Current Share Price	AU$3.47
52 Week High	AU$3.83
52 Week Low	AU$3.40
Beta	1.02
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-9.40%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MYXDA	AU Pharmaceuticals	AU Market
7D	-9.4%	-4.9%	-2.7%
1Y	n/a	-9.3%	6.5%

Return vs Industry: Insufficient data to determine how MYXDA performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MYXDA performed against the Australian Market.

Price Volatility

Is MYXDA's price volatile compared to industry and market?
MYXDA volatility
MYXDA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.3%
Market Average Movement	8.0%
10% most volatile stocks in AU Market	16.8%
10% least volatile stocks in AU Market	3.1%

Stable Share Price: MYXDA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MYXDA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Shawn O’Brien	www.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

Mayne Pharma Group Limited Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
MYXDA fundamental statistics
Market cap	AU$305.36m
Earnings (TTM)	-AU$263.34m
Revenue (TTM)	AU$424.80m

0.7x

P/S Ratio

-1.2x

P/E Ratio

Is MYXDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYXDA income statement (TTM)
Revenue	AU$424.80m
Cost of Revenue	AU$253.77m
Gross Profit	AU$171.03m
Other Expenses	AU$434.37m
Earnings	-AU$263.34m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Feb 23, 2023

Earnings per share (EPS)	-3.07
Gross Margin	40.26%
Net Profit Margin	-61.99%
Debt/Equity Ratio	72.8%

How did MYXDA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/01/25 07:57
End of Day Share Price	2023/01/24 00:00
Earnings	2022/06/30
Annual Earnings	2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	APP Securities Pty Ltd.
Russell Wright	Barclay Pearce Capital Pty Limited
John Hester	Bell Potter